TremRx Overview
- Status
-
Out of Business
- Employees
-
3

- Latest Deal Type
-
Out of Business
TremRx General Information
Description
Developer of a proprietary technology platform designed to discover prophylactic and therapeutic vaccines. The company's platform develops effective vaccines that are delivered to the upper layers of skin rather than into muscle like conventional vaccines that can mediate a dramatically strong and effective immune response against viruses and bacteria, enabling users to stay healthy and build immunity.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 67 Broad Street
- Boston, MA 02109
- United States
TremRx Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Out of Business | 01-Mar-2019 | Completed | Out of Business | |||
1. Seed Round | Completed | Startup |
TremRx Patents
TremRx Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-9416371-B2 | T-cell vaccination with viral vectors via mechanical epidermal disruption | Active | 31-Oct-2008 | 000000000 | |
US-8691502-B2 | T-cell vaccination with viral vectors via mechanical epidermal disruption | Active | 31-Oct-2008 | 000000000 | |
US-20110274649-A1 | T-cell vaccination with viral vectors via mechanical epidermal disruption | Granted | 31-Oct-2008 | 000000000 | |
US-20140186298-A1 | T-cell vaccination with viral vectors via mechanical epidermal disruption | Granted | 31-Oct-2008 | C12N15/86 |